Immutep Limited

Contributing Author

Recent Articles by Immutep Limited

Jun-23	Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases IMMP GlobeNewswire
May-27	Immutep's Efti with Radiotherapy & KEYTRUDA (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma IMMP GlobeNewswire
May-15	Immutep's Efti with KEYTRUDA (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer IMMP GlobeNewswire
May-05	Immutep's Efti in Combination with KEYTRUDA (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1 IMMP GlobeNewswire